Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Application based on results from the TROPION-Breast01 Phase III trial
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
Combination shows consistent benefit across prespecified post-progression outcomes
It is the first autotaxin inhibitor to be investigated in cancer patients
The validations confirm the completion of the applications and commence the scientific review process
Subscribe To Our Newsletter & Stay Updated
